There have been four previous reports of human sera causing agglutination of stored but not of fresh red cells (1-4). The sera are of special interest for two reasons. Since the agglutinins are active against the patients' own stored cells as well as against cells from other donors, one must consider whether such patients represent examples of autoimmune disease. Of more immediate practical importance, the sera provide a new means for studying the red-cell storage defect, since the agglutinins detect in the erythrocyte membrane a hitherto unrecognized alteration that progresses during in vitro storage concurrently with deterioration in cellular metabolism.
AGGLUTINATION OF STORED ERYTHROCYTES BY
(Submitted for publication May 8, 1963 ; accepted July 22, 1963) There have been four previous reports of human sera causing agglutination of stored but not of fresh red cells (1) (2) (3) (4) . The sera are of special interest for two reasons. Since the agglutinins are active against the patients' own stored cells as well as against cells from other donors, one must consider whether such patients represent examples of autoimmune disease. Of more immediate practical importance, the sera provide a new means for studying the red-cell storage defect, since the agglutinins detect in the erythrocyte membrane a hitherto unrecognized alteration that progresses during in vitro storage concurrently with deterioration in cellular metabolism.
Characterization of the previously reported stored-cell agglutinins has been limited. The present communication describes detailed studies of a serum causing strong agglutination of stored human red cells. The serum factor responsible for the agglutination was shown to be a gamma macroglobulin. Studies of red cells during storage in vitro indicate that development of agglutinability is closely related to the alterations in erythrocyte glucose metabolism occurring during storage. Also included are the results of sixteen studies of erythrocyte survival in vivo that are designed to examine the relationship of agglutinability to nonviability of the stored cells.
METHODS
The patient was a 71-year-old woman whose chief complaints were abdominal swelling and progressive weakness. The principal positive physical findings were pallor and hepatosplenomegaly. Laboratory findings of special interest were: hemoglobin, 9.7 g per 100 ml; reticulocytes, 4.2%o; serum bilirubin concentration, nor-* Work supported by U. S. Public Health Service research grant G-2918 (C5) from the National Cancer Institute, Bethesda, Md. mal; total serum protein concentration, 7 g per 100 ml (albumin, 2.7 g, globulin, 4.3 g). Survival in vivo of Cr51-labeled, f resh, compatible, red cells of normal donors was moderately severely reduced, judged by redcell life-span (Cr51 tt, about 8 days) based on daily blood sampling for 1 week. Exploratory laparotomy revealed moderate hepatic enlargement, diffuse mesenteric and retroperitoneal lymph-node enlargement, and massive splenomegaly. Splenectomy was performed, and the patient's postoperative course was uneventful. Two units of blood were transfused before and two additional units during surgery. Although the patient was improved at the time of discharge and required no further transfusions, she died at home 7 months later of undetermined cause; necroscopy was not performed. The spleen removed at operation weighed 2,050 g and showed hyperplasia of the white pulp, with impaired follicle formation; each Malpighian corpuscle was surrounded by a margin of hyperplastic lymphoid cells. Lymph nodes revealed intact architecture, but were filled out with lymphoid elements without follicle formation. A liver sample from biopsy was not remarkable, and aspirated bone marrow revealed only generalized hyperplasia. A specific pathological diagnosis was not made.
Stndies of the serum factor
The patient's serum was obtained from clotted or defibrinated blood; plasma was obtained in acid-citrate dextrose anticoagulant solution.' Serum and plasma samples were stored frozen at -20°C until used. Coldwater-precipitable protein was prepared by diluting the patient's serum with 10 vol of cold, demineralized water; after three washings, the precipitate was dissolved in isotonic phosphate buffered saline at pH 7.4 . Additional pathologic sera were obtained from twelve patients with macroglobulinemia, two patients with 02A myeloma, and one patient with nonspecific hyperglobulinemia.2 Normal human macroglobulin was prepared from pooled plasma as described by Franklin and Stanworth (5). Paper electrophoresis was performed in a Spinco model R cell, with barbital buffer at pH 8.6, ionic strength 0.1. Immunoelectrophoresis was by the 1 ACD, formula A, National Institutes of Health, Bethesda, Md. 2 Several of these sera were made available through the courtesy of Dr. H. G. Kunkel, the Rockefeller Institute, New York, N. Y. method of Scheidegger as described by Wieme (6) . Analytical ultracentrifugation was carried out at 59,000 rpm at 20°C in a Spinco model E ultracentrifuge. Sucrose gradient density ultracentrifugation was performed as described by Kunkel (7) . Column chromatography was carried out with DEAE cellulose 3 (1 ml serum to 6 g DEAE cellulose) by stepwise elution with phosphate buffers-0.0175 M at pH 6.3, 0.1 M at pH 5.9, and 0.4 M phosphate containing 0.2 M sodium chloride at pH 5.2-and with Sephadex G-200 4 (1 ml serum separated on a column 2.0 x 40 cm, with isotonic buffered saline at pH 7.4 as the equilibrating and eluting solution). p-Hydroxymercuribenzoate5 (PMB), N-ethylmaleimide 5 (NEM), dl-penicillamine,5 glutathione 5 (GSH), oxidized glutathione5 (GSSG) and mercaptopyridoxine 6 were obtained from manufacturers. The compounds were added to serum (diluted 1/10 unless otherwise indicated) after being dissolved in isotonic buffered saline. Incubation was at 370 C or room temperature for 1 to 2 hours. Where indicated, after incubation, a sample of the treated serum was dialyzed for 16 to 24 hours at 4°C against 1,000 vol of isotonic buffered saline.
For agglutination tests, dilutions of serum were made in isotonic saline. The test cells were normal, group 0 red cells that had been stored sterile at 40 C in the presence of trisodium citrate, balanced oxalate, or acidcitrate detrose anticoagulants until they exhibited 4 + agglutination (i.e., > 90% of the cells agglutinated) when exposed to the patient's serum diluted 1/100. One volume of 5% red-cell suspension was well mixed on an opaque glass plate with an equal volume of diluted serum. The plate was gently rocked for exactly 3 minutes, and the reactions were recorded by gross inspection; on occasion, microscopic examination was also performed.
In vitro studies of erythrocyte changes Red cells. Blood from normal donors and from 30 patients with a variety of hematologic disorders was collected in sterile bottles containing ACD solution, balanced sodium and potassium oxalate, trisodium citrate, heparin, or disodium EDTA anticoagulants. In addition, red cells from 100 sterile clotted samples in bloodbank pilot tubing were examined, including one sample7 from an I-negative donor (8) . Most of the metabolic studies were performed on red cells from a single healthy donor whose erythrocytes were known to exhibit normal glucose-6-phosphate dehydrogenase (G6PD) activity and normal proportions of A, and A2 hemoglobin. Animal bloods were obtained aseptically from rats, rabbits, and dogs. Preparation of eluates from red cells and red-cell ghosts by heating at 560 C was performed as described by Chaplin and Cassell (9 pletion of erythrocyte membrane lipids by treatment with alumina was carried out as described by Lovelock (10) . Sickling was induced in fresh homozygous (SS) sickle-cell blood by equilibration with a 95% nitrogen: 5% carbon dioxide gas mixture; reversal of sickling was accomplished by re-equilibration with a 97% oxygen: 3% nitrogen mixture as described by Anderson and Chaplin (11) . Fresh red cells were exposed to the enzymes trypsin, papain, ficin, and bromelin as described by Mollison (12) . Crude neuraminidase was added in various concentrations to buffered saline suspensions of thrice-washed fresh red cells and incubated at 37°C for up to 2 hours.
In metabolic studies, red cells from fresh blood collected aseptically in ACD anticoagulant were washed three times in 10 vol of glucose-free phosphate-buffered isotonic saline at pH 7.4, with removal of as much buffy coat as possible after each centrifugation. 2-Desoxy-Dglucose,5 Na arsenite 5 (as Na m-arsenite), Na arsenate 5 (as dibasic salt), Na monoiodoacetate, Na fluoride,5 PMB,5 NEM,5 phlorizin,5 adenosine,5 adenine,5 inosine,5 and methylene blue6 (MB) were obtained from manufacturers. Adenosine and NEM were dissolved in dilute HCl and neutralized to pH 7.4 by NaOH. The other reagents were dissolved directly in buffered isotonic saline. The thrice-washed red cells were made to a 50% suspension in buffered saline containing the reagents above, and the mixture was incubated in a Dubnoff metabolic shaker at 60 oscillations per minute and 370 C for 1 to 2 hours. After incubation, the red cells were washed once with 10 vol of buffered saline, and a 5% suspension was immediately tested for agglutination as previously described.
In vivo studies of erythrocyte changes Transfusion studies were performed in thirteen volunteers. Six were in normal health; four were hematologically normal hospital patients; of the remaining three patients, one had acute myelomonocytic leukemia, one, sickle-cell trait, and one, chronic myelocytic leukemia. Altogether, 9 U of outdated blood8 stored in ACD Figure 1 ) demonstrated that the agglutinating activity of whole serum was concentrated in the macroglobulin fraction. Column chromatography on DEAE cellulose (14) and Sephadex G-200 (15) (Figure 2) revealed the agglutinating activity concentrated in the fractions richest in gamma macroglobulins. The 7 S20,, gamma globulin fraction eluted in the first DEAE-cellulose peak was incubated with stored cells in the presence and absence of added complement; no agglutination was observed, and subsequent exposure to antihuman globulin serum revealed no evidence of "incomplete" stored-cell agglutinating activity.
Treatment of a 1/10 dilution of serum with disulfide-splitting agents-d,l-penicillamine (16) (10 mg per ml), mercaptopyridoxine (16) (10 mg per ml), or GSH (17-21) (4 X 10-2 M)-resulted in complete loss of agglutinating activity and disappearance of the macroglobulin peaks previously -seen on ultracentrifugation. Reaggregation of the protein subunits did not occur after dialysis of the treated serum, nor was the agglutinating activity restored. Furthermore, stored red cells incubated with the treated serum either before or after dialysis failed to agglutinate upon the addition of rabbit antihuman globulin serum, nor did they appear "blocked" when exposed to the patient's untreated serum.
Sulfhydryl (SH)-binding agents such as PMB (22, 23) , GSSG (20, 21) , and Na arsenite (23) (24) (25) (26) at concentrations of 2 to 5 X 10-2 M abolished agglutinating activity. Ultracentrifugation patterns of the serum remained unchanged ( Figure 3) except for loss of the 28.8 S20,w peak from the Na arsenite-treated sample. After dialysis, strong agglutinating activity was restored in all samples. NEM (27) inhibited the agglutinating activity only at high concentrations (2 x 10-1 M); the inhibition was not reversible after dialysis. (28) . Since improved preservation of stored red cells has been reported after addition of certain purine nucleosides (29) (30) (31) , the effects of adenosine and inosine (0.03 to 10 mM) were studied in relation to the development of agglutinability.
The nucleosides were added to either thrice-washed red cells or whole blood and incubated for 1 hour at 370 C. An increased effect of inhibition or reversal of agglutinability was observed as the concentration of nucleoside was raised from 0.03 to 3 mM; further enhancement was not observed at 10 mM concentration. Results of an experiment using 33-day-old ACD blood are shown in Table   III . The ameliorating effect of adenosine is clearly evident. In this particular experiment, inosine showed no beneficial effect; in other experiments, moderate reduction in agglutinability was observed after incubation with inosine, although never so much as with adenosine. The combination of inosine with adenosine was not better than adenosine alone. That the agglutination phenoienon involved actual binding of the agglutinin to the cell membrane was demonstrated in each of three studies of elution of the agglutinin by heating for 10 minutes at 560 C. Table V illustrates the agglutinating activity demonstrable in eluates prepared from intact fresh and long-stored cells, and from ghosts prepared from long-stored cells previously exposed to MG serum. Striking agglutinating activity was present in the stored-cell eluate, and weak but undoubted activity in the eluate from fresh cells, despite the complete absence of agglutinates in the fresh-cell preparation. It is not possible to say whether the weakly positive eluate from fresh cells implies the presence of reactive sites on the "fresh" red cell in vivo, since the time for the in vitro sensitization and eluation procedures could be sufficient to permit a minimal "storage" effect to become manifest. The very low activity demonstrable in the eluate from the stored-cell ghosts suggests that preparation of the ghosts (by hypotonic lysis in weakly acidified water) either liberated or inactivated the agglutinin. That ghosts retain their ability to react with the agglutinin was shown by four absorption studies; a typical result is illustrated in Table VI 
In vivo studies of erythrocyte changes
Survival of stored cells after transfusion. Fresh red cells labeled with chromium, incubated with MG serum, and passed through Millipore filters showed an entirely normal initial survival and a normal disappearance rate over the succeeding month (Cr51 ti, 27.5 days). Figure 5 summarizes the results of the 15 survival studies carried out on 9 U stored blood (mean length of storage, 30.5 days). When whole blood (control) was administered, 71 Bromelin-treated blood after transfusion. Fresh Cr51-labeled red cells were exposed to bromelin for 15 minutes, then washed four times in 100 vol saline. A sample tested with a 1/100 dilution of MG serum revealed 4 + agglutination. The remaining cells (not exposed to MG serum) were infused to the original donor. Eighty-nine per cent were present in the circulation at 1 hour after infusion, 71% at 3 hours, and 22% at 20.5 hours.
Relationship of aggldtinability to chronological rcd-cell age. Fe59 was administered to a normal volunteer, and samples were obtained for storage studies at intervals over the succeeding 110 days. In vitro storage was continued long enough to render 30 to 40% of the cells agglutinable by MG serum. Radioactivity per gram of hemoglobin in the whole samples was then compared with that in suspensions from which the agglutinable cells had been removed. We reasoned that if the development of agglutinability was directly related to chronological cell age, then the ratios of radioactivity in suspensions of unagglutinable cells to radioactivity in the whole sample would be > 1.0 (maximum, approximately 1.4) during the early phases of the study, and would fall to < 1.0 (minimum, approximately 0.2) near the end of the life-span of the labeled cells. If, on the other hand, development of agglutinability was unrelated to chronological cell age, the ratios would approximate 1.0 throughout the study. The results are illustrated in Figure 6 ; five of the six samples revealed ratios between 0.92 and 1.02, indicating that the development of agglutinability during in vitro storage was unrelated to chronological red-cell age.
DISCUSSION
It is rare to encounter human sera that agglutinate stored red cells and leave fresh cells unaffected, but the phenomenon reported here is by no means unique; six other examples have been previously described (1) (2) (3) (4) Previously published descriptions of stored-cell agglutinins have not included detailed characterization of the responsible serum factor (s) by means of more recently developed laboratory techniques. The serum described by Brendemoen (1) agglutinated stored cells more strongly in the cold than at room temperature or 370 C. Since the commonly encountered cold agglutinins are macroglobulins (7, 37) , it is likely that the responsible factor in Brendemoen's patient was a high-molecular-weight serum globulin. The same inference may possibly be justified for Jenkins' and Marsh's patient (4) whose serum agglutinated stored cells at both low and high temperatures. In two other instances (2, 3), however, sera were reported to be optimally active at 370 C, suggesting that the responsible factors were more likely to have been 7 S20,w serum globulins (37) .
In the present instance, the serum's ability to cause agglutination of stored red cells has been shown to reside in the macroglobulin componient; the evidence is its concentration a) in the highmolarity effluent from the DEAE-cellulose column (Figure 2) (14) , b) in the first peak from the Sephadex G-200 column (Figure 2) (15) , and c) in the bottom fraction after sucrose gradient density ultracentrifugation (Figure 1) (7) . That it is the 18.8 S20,w fraction rather than the 28.8 Results indicate that development of agglutinability during storage is unrelated to in vivo chronological cell age. S20,w fraction that is responsible for the agglutinating activity is indicated by the retention of agglutinating activity despite the loss of the 28.8 S2o,w peak in the ultracentrifugation pattern of postdialysis serum after treatment with Na arsenite (Figure 3) . Integrity of the whole 18.8 S20,w molecule appears to be necessary for maintenance of the agglutinating property, since agglutination no longer occurs when the molecule is broken down into smaller subunits after treatment with disulfide-splitting agents. Similar loss of activity after S-S cleavage has been reported for a variety of macromolecular agglutinins by other workers (38, 39 (Tables I and  II) ; agglutinability increased with conditions favoring depletion of glucose and consequent depletion of high-energy phosphate compounds.
These observations were extended by studies employing purine nucleosides, notably adenosine, which have been shown to improve the viability of stored red cells (29-31) either a) by conversion at the red-cell membrane to ribose 5-phosphate, which can be further metabolized with resultant regeneration of ADP and ATP (40-47), or b) by providing the purine moiety to serve as substrate for ATP synthesis (30, 48, 49) . Adenosine was able to restore many agglutinable cells to the unagglutinable state (Table III) when added after storage, and it delayed the development of agglutinability if present during storage. It was particularly remarkable that when adenosine was added to stored cells already agglutinated by MG serum, many of the cells detached themselves from the formed agglutinates, presumably reflecting a restorative effect on their metabolism. Under normal conditions, the red cell derives its energy entirely from the metabolism of glucose, approximately 90%o via the glycolytic (Embden-Meyerhof) pathway and 10%o via the oxidative hexose monophosphate shunt (50, 51) . If the beneficial effects of adenosine on agglutinability of stored cells were related to restoration of cellular metabolism, increased agglutinability should result from treatment with compounds interfering with cellular metabolism. MB provides a case in point, although its metabolic effects are numerous and complex. It is known to stimulate the hexose monophosphate shunt and to increase glucose utilization and CO2 formation; in the presence of MB, erythrocyte oxygen uptake may increase as much as twentyfold (52) (53) (54) . Even in the absence of glucose, increased uptake of oxygen is observed that presumably results from utilization of intracellular phosphate esters (51); the rate of breakdown of triose phosphate is increased, and lactate is oxidized to pyruvate (53, 55) . Washed red cells contain almost no glucose and limited amounts of other substrates (56) . In the presence of MB, these substrates will be rapidly exhausted, which may explain the mechanism whereby fresh red cells are rendered agglutinable in its presence. The interpretation is consistent with the finding that substrate provided in the form of glucose or adenosine inhibited or reversed the agglutination-inducing effect of MB.
The effect of MB on G6PD-deficient cells differs from its effects on normal cells. Not only does the hexose monophosphate shunt fail, but pentose phosphate is not returned to the glycolytic pathway from the pentose shunt (57) . Fructose 6-phosphate and triose phosphate become undetectable, and glucose accumulates (53) . These differences may at least partly account for the more pronounced effect of MB in inducing agglutinability of G6PD-deficient cells and the lack of a protective or ameliorative effect of added glucose. It is difficult to understand why adenosine failed to counteract the effects of MB, at least in part, since Carson (57) has shown that G6PD-deficient cells are capable of metabolizing inosine in the presence of MB and since a restorative effect of adenosine was observed after its addition to G6PD-deficient cells stored in the absence of MB.
2-Desoxy-D-glucose has been shown to inhibit glycolysis and the growth of yeast (58, 59 ) and various animal tissues (60) (61) (62) (63) (64) . It is phosphorylated by hexokinase (65), but is not further metabolized, or else is metabolized only slowly; it also inhibits fructokinase, phosphohexoseisomerase, and G6PD in cultured human cells (66) , and decreases levels of ATP in human red cells (67) . In the present study, 2-desoxy-D-glucose rendered fresh cells agglutinable by Mg serum. At low concentrations of 2-desoxy-D-glucose (1.6 to 6.4 mmoles per ml cells), its deleterious effect was preventable or reversible by glucose or adenosine.
Iodacetate, arsenate, arsenite, and fluoride inhibit various enzymes and intermediate reactions in the glycolytic pathway of glucose metabolism (40, 57, 59, (67) (68) (69) (70) (71) . Fresh red cells became agglutinable in the presence of concentrations of these reagents comparable to those employed by other workers to demonstrate inhibitory effects on glucose metabolism. Since agglutinability was not affected by addition of adenosine, it is likely that irreversible changes had taken place in the various enzymes affected by the inhibitory reagents.
Phlorizin inhibits the transport of glucose across cell membranes (72, 73) as well as inhibiting intracellular glucose metabolism at various steps (74) . Although the effects of phlorizin on glucose transport have been confirmed for the human red cell (72, 73) , its effects on erythrocyte glucose metabolism have not been adequately studied. In the present experiments, whether by its membrane effect or its effect on intracellular metabolism, phlorizin rendered fresh cells agglutinable by MG serum.
PMB at low concentrations (1 to 3 umoles per ml cells) binds to SH groups on the red-cell membrane and slightly stimulates glycolysis (75) ; at higher concentrations (up to 7 mmoles per ml cells), it inhibits the pentose pathway (76) . Its effect on red-cell nucleotides, however, is not marked. In the present studies, PMB did not affect agglutinability of fresh cells until it was used at a concentration of 0.4 mmole per ml cells, or higher. It is not possible to state whether its effect was mediated through SH binding on the red-cell surface, or inhibition of cellular glucose metabolism, or both. At a concentration of 2.5 ,umoles per ml cells, NEM, another SH reagent, is known to bind to membrane SH groups and enter the red cell where it binds intracellular GSH; red-cell glucose consumption and lactate production are impaired (75) . At higher concentrations of NEM, inhibition of the pentose pathway occurs (76) . In this study, NEM did not affect agglutinability of fresh cells until it was used at a concentration of 2 mmoles per ml cells, or higher. As in the case of PMB, judgment must be reserved on the relative importance of the various mechanisms of NEM's effect on agglutinability of fresh red cells.
If agglutinability of red cells is related to disturbance of their glucose metabolism, as our study strongly suggests, then integrity of the red-cell membrane is intimately linked with that of cellular metabolism. Interference with glucose metabolism at different levels leads to at least one common result, namely, depletion of ATP, and this is also observed when red cells are stored in vitro (12, 40, 71, 77, 78 Agglutinability does not appear to be related to depletion of membrane lipids. Cells treated with alumina were not agglutinable, and the restorative effects of adenosine cannot be explained in terms of membrane lipids (81) . The effect of proteolytic enzymes to enhance agglutinability (Table VII) and the inhibition of absorption of agglutinin after pretreatment of cell ghosts with PMB (Table VI) suggest that the fundamental alteration responsible for agglutinability involves the protein moiety of the cell membrane.
Results of preliminary studies with hematologically abnormal cells (Table VIII and IX) are of considerable interest. The presence of a small number of agglutinable cells in fresh blood from patients with sickle-cell anemia raises the possibility of an abnormality of the erythrocyte membrane in this disease either consequent upon or possibly unrelated to the abnormality of hemoglobin structure. The enhanced effects of storage upon cells from patients with thalassemia minor, iron-deficiency anemia, and Coombs-positive acquired hemolytic anemia suggest a pre-existing abnormality in the cell membranes, or impaired glucose metabolism, or both, in these pathologic erythrocytes. Evidence for metabolic abnormalities in red cells from patients with acquired hemolytic anemia has been reported by Altman, Tabechian, and Young (82) and by Storti, Vaccari, and Baldini (83) .
The most provocative question raised by the present studies concerns the relationship of cell viability to agglutinability. Figure 5 throw considerable light on the problem, but do not provide a conclusive answer. Thirty per cent of the cells in the control bloods were so severely damaged that they were removed from the recipient's circulation within 1 Figure 5 support an important and close relationship between the two phenomena.
A less direct parallel between agglutinability and nonviability is provided by the data in Figure 6 indicating that development of agglutinability is not related to in vivo chronological cell age. Similarly, it is known from inl vivo survival studies that nonviable cells in stored blood are a random sample of the cell population and do not represent the chronologically "old" donor cells (12) . The latter finding has become more understandable in the light of recent chemical studies comparing in vivo and in vitro aging: the former is characterized primarily by a fall in enzyme levels (84) , and the latter, by a decline in highenergy phosphate compounds (71, 78) , while enzyme levels remain uncharged (85) .
If the stored-cell agglutination phenomenon is to be considered an example of autoimmune disease, it must be established that the peculiar properties of the patient's serum were somehow responsible for her disease. She exhibited anemia and a reduced red-cell life-span when she was admitted to the hospital, but there is no positive evidence that the hemolytic anemia resulted from her serum's capacity to agglutinate stored cells. Jenkins and Marsh (4) have suggested that the red cell aged in vivo might act as an antigen. As discussed above, however, the aging of red cells in vivo and in vitro are different processes, and the results in Figure 6 indicate that red cells "aged" in vitro become agglutinable in a random fashion, unrelated to their chronological age. Furthermore, after splenectomy the patient's anemia did not recur, despite persistence of high concentrations of the pathologic macroglobulin in her serum. It is tempting to speculate that the metabolism-dependent alteration in the red-cell membrane had a counterpart in in vivo membrane changes in other tissue cells, with the exposure or creation of new antigenic sites responsible for stimulating antibody formation. There is no evidence from the present study to support this view, nor is it by any means certain that the macroglobulin should be classified as an "antibody." Red-cell agglutination may occur in the absence of antibody (86) , and caution should be exercised before interpreting stored-cell agglutination as a true antigen-antibody reaction.
In the light of the above discussion and until there is more evidence from similar patients, interpretation of the physiologic significance of the stored-cell agglutinins must remain open and judgment reserved on whether they are autoimmune phenomena. As a means for the study of erythrocyte physiology, they have great promise, since important insights are sure to follow from increasing knowledge of the precise changes they detect in the membranes of normal and pathologic human red cells.
SUMMARY
Serum from a patient with macroglobulinemia was observed to cause strong agglutination of stored human red cells but to leave fresh cells unaffected. By means of column chromatography and sucrose gradient density ultracentrifugation, the agglutinating activity was shown to reside in the macroglobulin fraction of the serum. Agglutinating activity was irreversibly abolished when the macroglobulin was broken down by disulfidesplitting reagents. Agglutinating activity was abolished by exposure of the serum to p-hydroxymercuribenzoate, Na arsenite, and glutathione, but was restored after dialysis. The agglutinating activity of the serum was irreversibly abolished by exposure to N-ethylmaleimide.
Studies carried out to characterize conditions under which stored human red cells become agglutinable included the effects of temperature of storage, anticoagulant solutions, agents favorable to red-cell metabolism (glucose, adenosine, inosine, and adenine), agents deleterious to red-cell metabolism (methylene blue, 2-desoxy-D-gluCose, phlorizin, arsenite, arsenate, iodoacetate, fluoride), p-hydroxymercuribenzoate and N-ethylmaleimide, proteolytic enzymes (trypsin, papain, ficin, bromelin, and neuraminidase), and depletion of membrane lipid (alumina). 
